Apyx Medical (NASDAQ:APYX) Shares Cross Above 50-Day Moving Average – What’s Next?

Shares of Apyx Medical Corporation (NASDAQ:APYX) passed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $2.74 and traded as high as $3.11. Apyx Medical shares last traded at $3.0450, with a volume of 994,957 shares.

Trending Headlines about Apyx Medical

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Q3 revenue was $14.0 million, above analysts’ $13.29 million estimate, while the per-share loss of $0.04 was narrower than expected. Surgical Aesthetics revenue grew 17%, and Apyx said it successfully launched its power liposuction handpiece for the AYON system. Apyx Medical third-quarter 2026 results
• Positive Sentiment: Management reaffirmed 2026 revenue guidance of $59 million to $60 million and lowered its operating expense target to $41 million–$42.5 million, a cost-control signal. The revenue range brackets the $59.4 million consensus estimate. Apyx reaffirms guidance and tightens expense target
• Negative Sentiment: Apyx remains unprofitable: it posted a quarterly loss, and its reported net margin and return on equity were negative. Continued losses may temper the market’s response to the revenue beat and new product launch. Apyx reports Q3 loss and tops revenue estimates

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Maxim Group began coverage on shares of Apyx Medical in a report on Tuesday, September 29th. They set a “buy” rating and a $6.00 price objective for the company. HC Wainwright started coverage on shares of Apyx Medical in a research note on Monday, July 13th. They set a “buy” rating and a $7.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, September 21st. Finally, Zacks Research raised Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Apyx Medical presently has a consensus rating of “Moderate Buy” and an average price target of $6.50.

Apyx Medical Stock Down 4.2%

The stock’s 50 day moving average is $2.74 and its two-hundred day moving average is $3.58. The company has a quick ratio of 4.53, a current ratio of 5.68 and a debt-to-equity ratio of 3.19.

Apyx Medical (NASDAQ:APYX) last issued its earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.05. The company had revenue of $14.03 million for the quarter, compared to analysts’ expectations of $13.29 million. Apyx Medical had a negative net margin of 14.16% and a negative return on equity of 64.87%. Analysts predict that Apyx Medical Corporation will post -0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Apyx Medical

Several institutional investors have recently bought and sold shares of APYX. NewEdge Advisors LLC increased its holdings in shares of Apyx Medical by 38.5% in the 2nd quarter. NewEdge Advisors LLC now owns 95,815 shares of the company’s stock valued at $430,000 after acquiring an additional 26,640 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Apyx Medical during the 2nd quarter worth $144,000. AXQ Capital LP purchased a new stake in shares of Apyx Medical during the 2nd quarter worth $78,000. Nwam LLC lifted its stake in shares of Apyx Medical by 35.0% during the 2nd quarter. Nwam LLC now owns 17,239 shares of the company’s stock worth $77,000 after purchasing an additional 4,467 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new stake in Apyx Medical during the second quarter valued at about $14,683,414. 55.33% of the stock is owned by hedge funds and other institutional investors.

About Apyx Medical

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company’s platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical’s principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.